0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CCR5

CCR5

Brief Information

Name:C-C chemokine receptor type 5
Target Synonym:CCR-5,Chemokine (C-C Motif) Receptor 5 (Gene/Pseudogene),C-C Motif Chemokine Receptor 5 A159A,Chemokine Recptor CCR5 Delta32,C-C Chemokine Receptor Type 5,Chemokine Receptor CCR5,CD195 Antigen,C-C CKR-5,CCCKR5,IDDM22,CKR-5,CKR5,Receptors, CCR5,C-C Motif C
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:12
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CC5-H52P3 Human Human CCR5 Full Length Protein-VLP (HEK293)
CC5-H52D1 Human Human CCR5 Protein, Flag,His Tag
CC5-H52D1-structure
CC5-H52D1-sds
CC5-H52D1-elisa_1
CC5-H52D1-elisa_2

Part of Bioactivity data

CC5-H52D1-SPR
Human_FcRn_Heterodimer_Protein_SPR

Human CCR5, Flag,His Tag (Cat. No. CC5-H52D1) captured on CM5 chip via anti-His antibody can bind Anti-CCR5 antibody (Human IgG1) with an affinity constant of 0.0737 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).

CC5-H52D1-SPR
Human_FcRn_Heterodimer_Protein_SPR

Purified NA/LE Mouse Anti-Human CD195 (Clone: 2D7) (Mouse IgG2a) captured on CM5 chip via anti-mouse antibodies surface can bind Human CCR5, Flag,His Tag (Cat. No. CC5-H52D1) with an affinity constant of 7.51 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).

Synonym Name

CCR5,CMKBR5,CD195,CC-CKR-5,CHEMR13

Background

Receptor for a number of inflammatory CC-chemokines including CCL3/MIP-1-alpha, CCL4/MIP-1-beta and RANTES and subsequently transduces a signal by increasing the intracellular calcium ion level. May play a role in the control of granulocytic lineage proliferation or differentiation.5 Publications (Microbial infection) Acts as a coreceptor (CD4 being the primary receptor) of human immunodeficiency virus-1/HIV-1.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Maraviroc MVC; UK-427857 Approved Viiv Healthcare Celsentri, Selzentry Mainland China HIV Infections Godecke Gmbh 2007-08-06 HIV Infections; Acquired Immunodeficiency Syndrome; Arthritis, Rheumatoid Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
BMS-813160 BMS-813160 Phase 2 Clinical Bristol-Myers Squibb Company Pancreatic Neoplasms; Diabetic Nephropathies; Hyperplasia; Colorectal Neoplasms Details
BMS-687681 BMS-687681 Phase 1 Clinical Bristol-Myers Squibb Company Neoplasms Details
SB-728-HSC SB-728-HSC; SB-728-HSPC; SB-728mR-HSPC Phase 1 Clinical Sangamo Biosciences HIV Infections Details
GSK-706769 GSK-706769 Phase 1 Clinical Glaxosmithkline Plc HIV Infections; Arthritis, Rheumatoid; Autoimmune Diseases Details
Thioraviroc Phase 1 Clinical Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences HIV Infections Details
Vicriviroc SCH-D; MK-4176; SCH-417; Sch-417690 Phase 2 Clinical Merck & Co Inc Acquired Immunodeficiency Syndrome; HIV Infections; Colorectal Neoplasms Details
SB-728-T SB-728-T; SB-728mR-T Phase 2 Clinical Sangamo Biosciences HIV Infections Details
OB-002H OB-002; 5P12-RANTES Phase 1 Clinical HIV Infections Details
CAL-1-transduced hematopoietic stem cell gene therapy (Calimmune) Cal-1 Phase 2 Clinical Calimmune HIV Infections; Breast Neoplasms; Neoplasm Metastasis Details
Emtricitabine/Maraviroc/Tenofovir Disoproxil Fumarate Phase 1 Clinical University Of Texas Medical Branch, Oak Crest Institute Of Science, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Auritec Pharmaceuticals HIV Infections Details
Cenicriviroc mesylate/Tropifexor LJC-242 Phase 2 Clinical Novartis Pharma Ag Non-alcoholic Fatty Liver Disease Details
Cenicriviroc mesylate CVC; TAK-652; TBR-652; CCR5/CCR2 antagonist Phase 3 Clinical Tobira Therapeutics, Takeda Pharmaceutical Co Ltd Prediabetic State; HIV Infections; Acquired Immunodeficiency Syndrome; Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease; Liver Cirrhosis; Cholangitis, Sclerosing; Hepatic Insufficiency; Obesity; Cognition Disorders Details

This web search service is supported by Google Inc.

totop